Home
News
Create
Screeners
Insights
Vivimed Labs
6.
72
+0.27
(+4.19%)
Market Cap
₹55.72 Cr
PE Ratio
-1.53
Industry
Healthcare
Buy
Sell
Company Performance:
1D
+4.19%
1M
-2.33%
6M
-74.74%
1Y
-74.74%
5Y
+7.52%
View Company Insights
Latest news about Vivimed Labs
Vivimed Labs reschedules board meeting to May 30 for Q4FY26 results
3 days ago
Vivimed Labs Limited has postponed its board meeting from May 28 to May 30, 2026, to approve the audited financial results for the quarter and year ending March 31, 2026. The meeting will be held in Hyderabad to review standalone and consolidated results. The trading window for designated persons remains closed until 48 hours after the results are declared.
Vivimed Labs Schedules Board Meeting on May 28, 2026 to Approve Q4FY26 Financial Results
May 17, 2026
Vivimed Labs Limited Enters Corporate Insolvency Resolution Process
Apr 26, 2026
Vivimed Labs Limited Insolvency Process: CIRP Commences 15.04.2026
Apr 23, 2026
Vivimed Labs Submits Q4FY26 SEBI Compliance Certificate to Stock Exchanges
Apr 08, 2026
More news about Vivimed Labs
13
Mar 26
Vivimed Labs Reports Widened Q3 FY26 Loss at ₹165.66 Million on Lower Revenue
Vivimed Labs Limited reported significantly worsened financial performance for Q3 FY26 with net loss widening to ₹165.66 million from ₹74.45 million in Q3 FY25, while revenue declined to ₹116.31 million from ₹186.59 million. Nine-month results showed similar deterioration with loss increasing to ₹295.07 million and revenue falling to ₹342.33 million. Consolidated results mirrored standalone trends with Q3 FY26 loss at ₹165.54 million. Auditors expressed qualified conclusions citing unprovided interest charges of ₹164.52 million for the quarter and ongoing forensic audit evaluations.
Vivimed Labs
6.
72
+
0.
27
(+
4.
19
%)
1 Year Returns:
-74.74%
Industry Peers
Sun Pharmaceutical
1,799.20
(-
2.
45
%)
Divis Laboratories
6,667.00
(-
1.
92
%)
Torrent Pharmaceuticals
4,410.80
(-
2.
80
%)
Cipla
1,401.00
(-
1.
21
%)
Dr Reddys Laboratories
1,303.50
(-
1.
18
%)
Zydus Life Science
1,077.70
(-
0.
75
%)
Lupin
2,267.70
(-
0.
38
%)
Mankind Pharma
2,375.60
(-
1.
85
%)
Aurobindo Pharma
1,426.40
(-
0.
66
%)
Laurus Labs
1,362.00
(-
1.
43
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO
Cyclical Trend
Events Calendar